As the number of mega-mergers have increased in recent years, and the purchase price of innovative companies rises, it is apparent that many lucrative buyouts fail to meet expectations, although a few outperform from time to time.
Several recent Celgene Corp. patents detail the development of proteolysis targeting chimera (PROTAC) compounds comprising a cereblon (CRBN)-binding moiety covalently linked to an interleukin-1 receptor-associated kinase 4 (IRAK-4)-targeting moiety via a linker.
Scientists at Bristol Myers Squibb Co. and Celgene Corp. have synthesized proteolysis targeting chimera (PROTAC) compounds comprising a cereblon (CRBN) E3 ubiquitin ligase-binding moiety coupled to a protein-targeting moiety through a linker.
Celgene Corp. has divulged proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety covalently linked to a MAP kinase-activated protein kinase 2 (MAPKAPK2; MK2)-targeting moiety via a linker.
Celgene Corp. has patented sphingosine 1-phosphate S1P5 receptor (EDG8) modulators reported to be useful for the treatment of Alzheimer’s disease and multiple sclerosis.
Bristol Myers Squibb Co. and Celgene Corp. have described MAP kinase-activated protein kinase 2 (MAPKAPK2; MK2) inhibitors reported to be useful for the treatment of inflammation, cancer, fibrosis, autoimmune disorders, cardiovascular disorders, metabolic disorders and cerebrovascular disorders.
Celgene Corp. has identified substituted imidazopyrazine compounds characterized as interleukin-1 receptor-associated kinase 3 (IRAK-3; IRAK-M) ligands and thus reported to be useful for the treatment of cancer, autoimmune diseases and inflammatory disorders.
Celgene Corp. has described heterocyclic protein-arginine deiminase type-4 (PADI4) inhibitors reported to be useful for the treatment of aging, autoimmune diseases, pain, asthma, inflammatory bowel diseases, AIDS, cancer and Alzheimer's disease, among others.
Taking aim at big pharma’s current penchant for acquisition over in-house innovation, Sen. Elizabeth Warren (D-Mass.) is asking the Federal Trade Commission (FTC) to consider the impact a biopharma merger, whether it’s proposed or a done deal, may have on future innovation.
Celgene Corp. has disclosed sphingosine 1-phosphate receptor 5 (S1PR5; EDG8) modulators reported to be useful for the treatment of Alzheimer's disease and multiple sclerosis.
